PharmaVentures' new Vice President recruited to lead Pricing and Market Access practice

Ralph Hughes joins the corporate advisory team to support clients in bringing their products to market

LONDON, Sept. 27, 2022 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.

Ralph has built extensive experience in Pricing and Market Access, and also in Commercial assessment, through his various roles in the pharmaceutical industry. For Mundipharma, he was responsible for the access and commercial launch strategy for key brands and for developing the commercial assessments for potential assets. At Pfizer, he developed market access and pricing strategies globally and across multiple disease areas for early-stage and in-market assets. He has developed marketing campaigns, forecasts, Health Technology Assessments, price guidance, real world data studies, market research and economic models.

Ralph developed economic models for NICE's clinical guidelines programme. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine, and a BSc in Biomedical Sciences from Newcastle.

Through his career to date, Ralph has developed a strong understanding of what it takes to overcome access hurdles and to commercialise a novel therapeutic.

Fintan Walton, Founder and CEO of PharmaVentures, said, "We are delighted to welcome Ralph to the PharmaVentures team. Many of our clients need high-quality pricing and market access guidance that will strengthen their narrative and position in development and deal making and we are pleased to support them in this crucial area."

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
Phone: +44 (0) 1865 332700
[email protected]

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures' deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures' services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, and fundraising)
• Pricing and Market Access

https://www.pharmaventures.com/pricing-and-market-access/ 

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

SOURCE PharmaVentures